-
First, positive interim analysis results were obtained for the phase 2b clinical trial of up to XW003 (Ecnoglutide) obesity
Time of Update: 2022-11-04
, a clinical-stage biotechnology company focused on the research and development of innovative therapies for the treatment of chronic metabolic diseases, today announced the positive interim analysis results of its ongoing Phase 2b clinical trial of XW003 (Ecnoglutide) obesity.
-
Express significantly improves many liver indicators! Multi-target NASH innovative drug Phase 2b clinical outcomes are positive
Time of Update: 2022-10-14
AXA1125 clinical data (Image source: Reference [3]) EMMPACT is a global, double-blind, placebo-controlled, dose-assay 2b trial to examine the safety, tolerability, and efficacy of AXA1125 in patients treated with NASH.
-
interferon α-2b in the treatment of e-antigen-positive hepatitis B and improvement of inflammatory factors and hemodynamics
Time of Update: 2022-09-30
Background: Chronic hepatitis B (CHB) is one of the most prevalent infectious diseases worldwide, caused by the hepatitis B virus (HBV), which is highly contagious. According to statistics, the number
-
Human Eye Choroid Melanoma Cell MuM-2B Culture Instructions (Updated in 2022)
Time of Update: 2022-09-14
Human eye choroid melanoma cell MuM-2B Growth characteristics
Human eye choroid melanoma cell MuM-2B Growth characteristics
Human eye choroid melanoma cell MuM-2B Growth characteristics
Human eye choroid melanoma cell MuM-2B Growth characteristics
Human eye choroid melanoma cell MuM-2B Growth characteristics
-
Courier's potential "first-in-class" DMD new drug Phase 2b clinical trial results published!
Time of Update: 2022-09-06
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamToday, Santhera Pharmaceuticals and ReveraGen BioPharma jointly announced the positive results of the VISION-DMD clinical 2b trial of Duchenne muscular dystrophy (DMD) investigational drug vamorolone, published in the leading journal JAMA Neurology .
-
Electrochemiluminescence analysis assists FGF19 target - NASH clinical phase 2b study in nonalcoholic steatohepatitis
Time of Update: 2022-08-30
0 Eleven (30%) of 37 patients in the mg group (difference 10% [−9 to 30]; p=0 12) had at least one stage of improvement in fibrosis and no worsening of NASH, but did not meet the prespecified The dose response was significant (p=0·55) .
-
antibody reached the primary efficacy endpoint of Phase 2b clinical trial
Time of Update: 2022-04-29
Image source: Reference [2] In this multicenter, open-label, repeat-dose Phase 2b clinical trial, 23 patients with congenital HI who had not adequately controlled hypoglycemia with standard therapy were treated with RZ358 to evaluate Drug safety and tolerability, pharmacokinetics and glycemic efficacy .
-
Significantly improved children's hereditary hypoglycemia, innovative monoclonal antibody reached the primary efficacy endpoint of Phase 2b clinical trial
Time of Update: 2022-04-27
Image source: Reference [2]In this multicenter, open-label, repeat-dose Phase 2b clinical trial, 23 patients with congenital HI who failed to adequately control hypoglycemia with standard therapy received RZ358 to evaluate the safety and tolerability of the drug , pharmacokinetics and glycemic efficacy .
Retrieved March 23, 2022, from https:// en/Rezolute-Announces-Positive-Results-from-the-Phase-2b-RIZE-Study-of-RZ358-in-Congenital-Hyperinsulinism.
-
Tengshengbo drug BRII-179 was used for the functional cure of hepatitis B in phase 2a/2b clinical completion of the first subject administration
Time of Update: 2022-01-10
HK), a multinational company dedicated to the development of innovative therapies for patients’ unmet needs and major public health diseases, today announced that BRII-179 (VBI-2601) treats chronic hepatitis B virus (HBV) infection Phase 2a/2b clinical trials have completed the first subject's administration .
-
MimiVac peptide mimic tumor vaccine received FDA approval for 2b clinical trial for the treatment of glioblastoma
Time of Update: 2021-12-06
November 19, 2021/eMedClub News/--Recently, a clinical stage biotechnology company MimiVac LLC announced , SurVaxM received the US Food and Drug Administration (FDA) approval notice in the 2b trial phase to evaluate the effectiveness of the newly diagnosed glioblastoma .
-
Treating depression, showing positive potential, hallucinogenic mushroom ingredients reach phase 2b clinical endpoint
Time of Update: 2021-12-03
A few days ago, COMPASS Pathways announced that it is developing psilocybin therapy COMP360 and has reached the primary endpoint in a Phase 2b clinical trial for the treatment of patients with refractory depression .
-
Significantly reduce blood lipids, innovative antisense oligonucleotide therapy reaches phase 2b clinical endpoint
Time of Update: 2021-12-01
On November 24, 2021, Ionis pharmaceuticals announced that vupanorsen, jointly developed with Pfizer, has reached primary and critical secondary clinical endpoints in phase 2b clinical trials .
-
Nat Med: Application of Aramchol in patients with non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled Phase 2b trial
Time of Update: 2021-10-20
The most recently conducted ARREST is a 52-week double-blind, placebo-controlled Phase 2b trial that randomized 247 patients with NASH (Aramchol 400 mg, 600 mg, and placebo groups were n = 101, n = 98 and n = 48; NCT02279524) .
-
NEJM: ALVAC-HIV vaccination program failed in South Africa Phase 2b-3 clinical study
Time of Update: 2021-03-30
Prevention During the 24-month follow-up, 138 participants in the vaccine group and 133 participants in the placebo group were diagnosed with HIV-1 infection (hazard ratio 1.
During the 24-month follow-up, 138 participants in the vaccine group and 133 participants in the placebo group were diagnosed with HIV-1 infection (hazard ratio 1.
-
NEJM: ALVAC-HIV vaccination program failed in South Africa Phase 2b-3 clinical study
Time of Update: 2021-03-26
Prevention During the 24-month follow-up, 138 participants in the vaccine group and 133 participants in the placebo group were diagnosed with HIV-1 infection (hazard ratio 1.
During the 24-month follow-up, 138 participants in the vaccine group and 133 participants in the placebo group were diagnosed with HIV-1 infection (hazard ratio 1.